NCT04002089View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 26, 2019

Primary Completion Date

December 2, 2019

Study Completion Date

December 2, 2019

Conditions
Bunion
Interventions
DRUG

Exparel Injectable Product

bupivacaine liposome injectable suspension

DRUG

Bupivacaine

1.3%, 13.3 mg/mL

Trial Locations (1)

77401

First Surgical Hospital, Bellaire

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY